NCT01052792已完成1 期
Open Label Randomised,Two-treatment,Two-period,Two-sequence,Single-dose, Crossover,Comparative Bioequivalence Study of Naproxen Sodium 550 mg Tablets With ANAPROX® DS 550 mg Tablets in Healthy,Adult, Human Subjects Under Fed Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Bioequivalence based on Cmax and AUC parameters
研究概览
简要总结
An open label randomised, two-treatment,two-period, two-sequence, single-dose, crossover, comparative bioequivalence study.
详细描述
The study was an open label, randomised, two-treatment,two-period, two-sequence, single-dose, crossover,comparative bioequivalence study of Naproxen Sodium 550 mg tablets (containing naproxen 500 mg) manufactured by Dr. Reddy's Laboratories, ltd, Generics, India compared with ANAPROX® DS 550 mg tablets (containing naproxen 500 mg) of Roche Pharmaceuticals, Roche Laboratories Inc. 340 Kingsland Street, New Jersey; in healthy,adult, human subjects under fed conditions with a wash out period of 10 days between two periods.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy human subjects within the age range of 18 to 45 years.
- •Non-smokers since at least six months.
- •Willingness to provide written informed consent to participate in the study.
- •Body-mass index of ≥ 18.5 kg/m2 and ≤ 24.9 kg/m2, witQ body weight not less than 50 kg.
- •Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening.
- •Normal 12-lead ECG or one with abnormality considered to be clinically insignificant.
- •Normal chest X-ray PA view.
- •Comprehension of the nature and purpose of the study and compliance with the requirement of the protocol.
- •Female Subjects:
- •of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s) such as condoms, foams jellies, diaphragm, intrauterine device {IUD}, or abstinence or postmenopausal for at least 1 year, or surgically sterile {bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject.
排除标准
- •Personal/family history of allergy or hypersensitivity to Naproxen sodium or allied drugs.
- •Past history of anaphylaxis or angioedema.
- •Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.
- •Presence of any clinically significant abnormal values during screening e.g significant abnormality of liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.
- •Any cardiac, renal or liver impairment any other organ or system impairment.
- •History of seizure or psychiatric disorders.
- •Presence of disease markers of HIV 1 and 2, and hepatitis B and C virus.
- •Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study {one drink is equal to one unit of alcohol {one glass wine half pint beer, and one measure (one ounce) of spirit].
- •Consumption of xanthine containing derivatives (coffee, tea, cola drinks, chocolate) within 48 hours before check-in of each period.
- •Use of any recreational drug or a history of drug addiction.
- •Participation in any clinical trial within the past 3 months.
- •Inaccessibility of veins in left and right arm.
- •Donation of blood (one unit or 350 mL) within 3 months prior to receiving the first dose of study medication.
- •Receipt of any prescription drug therapy within four weeks or over-the-counter {OTC) drugs within two weeks prior to receiving the first dose of study medication or repeated use of drugs within the last four weeks.
- •An unusual diet, for whatever reason e.g. low sodium diet for two weeks prior to receiving any medication and through out subject's participation in the study.
- •Consumption of grapefruit-containing food or beverages within 7 days prior to receiving the first dose of study medication in both the periods.
- •Recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 24 hours prior to the study.
- •Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding.
研究组 & 干预措施
Naproxen Sodium 550 mg Tablets
Experimental
Naproxen Sodium 550 mg Tablets of Dr. Reddy's Laboratories Limited
干预措施: Naproxen Sodium (Drug)
Anaprox DS 550mg Tablets
Active Comparator
Anaprox DS 550mg Tablets of Roche Pharmaceuticals Inc
干预措施: Naproxen Sodium (Drug)
结局指标
主要结局
Bioequivalence based on Cmax and AUC parameters
时间窗: 3 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fasting ConditionHealthyNCT01052129Dr. Reddy's Laboratories Limited26
已完成
1 期
Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsules Under Fasting ConditionsHealthyNCT01045642Dr. Reddy's Laboratories Limited38
已完成
1 期
Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsule Under Fed ConditionsHealthyNCT01045434Dr. Reddy's Laboratories Limited62
尚未招募
1 期
An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Two-way Crossover, Oralcomparative Pharmacokinetic（PK）Study of Lacosamide Extended-Release Tablets , Adult, Human Subjects Under Fasting Conditions.EpilepsyNCT05788159Overseas Pharmaceuticals, Ltd.16
已完成
4 期
Bioavailability study of Curcuminoids capsules of Triokka Pharmaceuticals Private Limited, India with Meriva-SR of Throne Research Inc., USA in 8 Healthy adult human male subjects under fasting conditions.CTRI/2016/05/006938Troikaa Pharmaceuticals Limited8